Actively Recruiting
Evaluating Luvometinib Combined With Anlotinib for KRAS-Mutated Metastatic Non-Small Cell Lung Cancer A Phase 2 Open-Label Study
Led by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Updated on 2026-09-02
48
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of luvometinib and anlotinib in patients with KRAS-mutated metastatic non-small cell lung cancer who have previously received treatment. This phase 2 study aims to assess the safety and effectiveness of this drug combination in this specific patient group, focusing on those with advanced disease who have progressed after at least one prior systemic therapy. Participants receive oral doses of luvometinib combined with anlotinib. The study starts with a safety run-in period where different dose combinations are tested to find the optimal dosing. After this, about 30 patients will continue treatment at the recommended doses to further evaluate how well the combination works and its safety profile. Treatment is given sequentially, with doses adjusted based on safety findings. Throughout the study, participants will be closely monitored with various assessments including measuring tumor response using RECIST v1.1 criteria over up to 24 months. The main outcome is the objective response rate. Additional measures include duration of response, time to response, disease control rate, progression-free survival, safety, and pharmacokinetics of the drug combination. Participants will have regular visits for evaluations and follow-up during and after treatment to track these outcomes and ensure safety.
CONDITIONS
Brief Title
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Research Team
B
BAOHUI HAN
W
Wei Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here